Targeting IgE and Th2-Cytokines in Allergy: Brief Updates on Monoclonal Antibodies and Antibody Gene Therapy

The search for an effective treatment of allergic conditions is ongoing global health challenge due to the high prevalence allergies. Epinephrine and glucocorticosteroids remain oldest most widely used regimen allergy, these medications are short relief. In extreme allergy manifestations, current options aim use monoclonal antibody (mAb) target pathological pathways inflammation involving mast cells, eosinophils, basophils. These cells have propensity induce allergic-inflammatory response. Studies shown that they responsible several diseases, such as asthma, atopic dermatitis, rhinitis, conjunctivitis. evaluating antibodies against serum IgE (Omalizumab), Th-2 cytokines, IL-4, IL-13 (dupilumab), IL-5 suggest attenuation symptoms improvement in patients’ overall well-being. However, factors cost production (i.e., purification), host immunogenicity, safety, efficacy hindered availability purified mAb developing countries. Gene therapy a promising tool treating emerging studies suggested gene may be future cases manifestations. This paper describes severe responses associated limitations. It explores prospects modulating episodes.